Narayana Hrudayalaya liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

4.39×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.15×	2.15×	2.18×	1.75×	1.31×
2.07×	2.07×	2.09×	1.65×	1.24×
1,184	1,184	1,437	1,104	406
2,105	2,105	1,356	836	307

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NH₹1,714.50

Narayana Hrudayalaya Ltd.

· Pharma & Health

₹ CrorePeersAPOLLOHOSP MAXHEALTH FORTIS NEULANDLAB NATCOPHARM LALPATHLAB SAILIFE COHANCEMcap ₹35,038 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	4.39
Current Ratio	1.31	1.75	2.18	2.15	2.15
Quick Ratio	1.24	1.65	2.09	2.07	2.07
Cash, Equiv & ST Investments	406.1	1,103.5	1,437.2	1,184.3	1,184.3
Working Capital	306.7	835.7	1,356.0	2,104.9	2,104.9

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.